In addition to ALCL, BV has shown efficacy as a single agent in other T-NHLs (NCT01421667).81 In addition to systemic lymphomas, BV was also utilized in primary CD30+ cutaneous lymphomas and showed encouraging efficacy.82 A phase 3 randomized multicenter trial (ALCANZA, NCT01578499) was conducted to evaluate single-agent BV vs a control arm of the investigator’s choice of standard therapies in patients with CD30+ primary cutaneous ALCL or MF. Here, TNFRSF8 is linked to mycosis fungoides.